XTL Biopharmaceuticals Statistics
Share Statistics
XTL Biopharmaceuticals has 8.81M
shares outstanding. The number of shares has increased by 191.25%
in one year.
| Shares Outstanding | 8.81M |
| Shares Change (YoY) | 191.25% |
| Shares Change (QoQ) | 15.9% |
| Owned by Institutions (%) | 0.04% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 15 |
| FTD / Avg. Volume | 0.19% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -3088.68 and the forward
PE ratio is null.
XTL Biopharmaceuticals's PEG ratio is
30.89.
| PE Ratio | -3088.68 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 2.48 |
| P/FCF Ratio | -7.79 |
| PEG Ratio | 30.89 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for XTL Biopharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.93,
with a Debt / Equity ratio of 0.
| Current Ratio | 9.93 |
| Quick Ratio | 9.93 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-222.75 |
| Employee Count | 8 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -44.58% in the
last 52 weeks. The beta is 0.99, so XTL Biopharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.99 |
| 52-Week Price Change | -44.58% |
| 50-Day Moving Average | 1.26 |
| 200-Day Moving Average | 1.89 |
| Relative Strength Index (RSI) | 50.73 |
| Average Volume (20 Days) | 8,034 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -765K |
| Net Income | -1.78K |
| EBITDA | -764K |
| EBIT | -765K |
| Earnings Per Share (EPS) | 0 |
Full Income StatementBalance Sheet
The company has 1.4M in cash and 0 in
debt, giving a net cash position of 1.4M.
| Cash & Cash Equivalents | 1.4M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -158.25M |
| Total Assets | 9.28M |
| Working Capital | -480K |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -707K
and capital expenditures 0, giving a free cash flow of -707K.
| Operating Cash Flow | -707K |
| Capital Expenditures | n/a |
| Free Cash Flow | -707K |
| FCF Per Share | 0 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
